Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 open label randomized multicenter trial to assess the efficacy and safety of the dispersible arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg tablets in comparison with Coartem dispersible in pediatric patients with acute uncomplicated Plasmodium falciparum malaria

Trial Profile

A Phase 3 open label randomized multicenter trial to assess the efficacy and safety of the dispersible arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg tablets in comparison with Coartem dispersible in pediatric patients with acute uncomplicated Plasmodium falciparum malaria

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arterolane/piperaquine (Primary) ; Artemether/lumefantrine
  • Indications Malaria
  • Focus Registrational; Therapeutic Use
  • Sponsors Sun Pharmaceutical Industries

Most Recent Events

  • 19 Oct 2017 New trial record
  • 29 Aug 2017 Results published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top